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SUMMARY
Although noroviruses (NoVs) were the first viral agents linked to gastrointestinal disease, 
for a long time they have been considered secondary cause of gastroenteritis, second to 
rotaviruses as etiologic agents. The development of molecular techniques in diagnosing 
NoV provided a clearer insight into the epidemiological impact of these viruses, which 
are currently recognized not only as the leading cause of non-bacterial gastroenteritis 
outbreaks, but also as a major cause of sporadic gastroenteritis in both children and 
adults. This review focuses on the required knowledge to understand their morphology, 
genetics, transmission, pathogenesis, and control. Since no vaccine is available, preven-
tion of NoV infection relies mainly on strict community and personal hygiene measures.
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Figure 1 – Bovine calicivirus, viral particles extracted 
from stool sample (Stewart McNulty, Veterinary Sciences, 
Queen’s University, Belfast). Negative dye technique 
by direct electron microscopy. Magnification 33,000 X. 
Available at: http: //www.qub.ac.uk
Figure 2 – Norovirus genomic organization. Localization of 
the three ORFs and the Pol  region used for the design of 
the primer pool used in the RT-PCR for the identification of 
genogroups and genotypes. From Atmar & Estes, 2001.29
INTRODUCTION
Acute gastroenteritis is one of the most common diseases 
in humans; in the United States, it is the second leading 
cause for reporting, followed by respiratory infections1. 
A billion cases of acute diarrhea are estimated to occur 
yearly in children and adults worldwide2. Gastroenteritis 
is usually expressed as a mild diarrhea, but it can be seen 
as a severe form with enhanced symptoms (nausea and 
vomiting), possibly leading to dehydration and death. The 
annual mortality associated with gastroenteritis has been 
estimated as four to six million people2.
The etiology of diarrheas can involve several agents, 
such as viruses, bacteria, and parasites. Bacterial agents are 
relatively more important in developing countries, where-
as viral agents are more relevant in industrialized coun-
tries. The importance of these agents is related to hygiene 
and sanitation conditions for the population1. In 1972, a 
27-nm viral particle was discovered in an infectious filtrate 
of human fecal samples over a gastroenteritis outbreak in 
Norwalk, Ohio3. Since then, the number of viral agents as-
sociated with gastroenteritis has progressively increased, 
with rotaviruses4, astroviruses5, and Norwalk-like viruses6 
being identified.
Currently, most gastroenteritis in children are con-
sidered to be caused by viruses included in four different 
families: Reoviridae (rotavirus), Caliciviridae (norovirus 
and sapovirus), Astroviridae (astrovirus), and Adenoviri-
dae (adenovirus)7.
VIRAL PARTICLE STRUCTURE OF NOROVIRUSES
Virions consist of a capsid and a nucleic acid measuring 
about 27 to 30 nm in diameter. They have no envelope. The 
nucleocapsid is rounded and exhibits an icosahedral sym-
metry. The surface structure reveals a regular model with 
distinct features8. The capsomere arrangement is clearly 
visible (Figure 1).
The virus genome consists of a linear molecule of sin-
gle-strand RNA with a positive polarity. The genomes with 
these features serve as mRNA. As soon as they enter the 
target-cell, they are bound to cell ribosomes and protein 
translation occurs. The genome RNA serves as a template 
for a complementary negative strand being transcribed 
into genome RNA through the viral polymerase. The com-
plete genome contains approximately 7.5 kb and consists 
of 45%-56% of cytosine + guanine (C + G). The genome 
5’ end presents the VPg protein, having an essential role 
in virus infectivity and initial translation; in the 3’ end, 
the poli A tail addition occurs after the gene synthesis and 
its function is giving stability to the molecule and helping 
translation8.
The three open read frames (ORF) of the virus ge-
nome can be observed in Figure 2: the first ORF encodes a 
194-kDa polyprotein which is cleaved by the virus prote-
ase 3C into six likely proteins, including RNA-dependent 
RNA polymerase. Thus, the 5’-end in the genome encodes 
a precursor of non-structural proteins involved in the vi-
rus transcription and replication9. The second ORF en-
codes a 60-kDa capsid protein (VP1), a structural protein 
with a major role in virus replication10. The third ORF is 
considered the most variable region in the genome and en-
codes the 23-kDa basic protein (VP2) interacting with the 
genome RNA when the virion formation occurs11.
NOMENCLATURE AND CLASSIFICATION
Because of low viral (NoV) load in feces and difficult 
spread in both cell culture and laboratory animals, the vi-
rus classification was defined only from 1990. Since then, 
some calicivirus genomes have been sequenced, allowing 
framing most of these viruses into the Caliciviridae fam-
ily12.
In 2005, a new classification system was established 
and based on ORF2 phylogenetic analyses of 164 NoV 
sequences. NoVs can be subdivided into five genogroups 
(GI, GII, GIII, GIV, GV), consisting of at least 31 genetic 
clusters or genotypes: 8 genotypes in GI genogroup, 17 in 
GII, 2 in GIII, 1 in GIV, and 1 in GV13. Across all of them, 
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GI and GII are the genogroups presenting the largest ge-
netic diversity; six new genotypes were new genotypes de-
fined and described: GI/8 in serogroup GI and GII/13-17 
in genogroup GII14. NoVs with genogroups GI, GII, and 
GIV are found in humans, except for the sample of NV 
S11/GII found in swine; genogroups GIII and GV are 
found in cattle and mice, respectively15. Recently, molecu-
lar epidemiology studies have demonstrated 70% of NoV 
outbreaks are caused by the variant genotype GII.416,17.
PATHOGENESIS AND REPLICATION
Human caliciviruses cause infection predominantly by the 
oral route. Virions are stable in acid and they can survive 
after passing through the stomach. NoVs are highly infec-
tious due to the combination of low infecting dose (DI 
50 < 20 virus particles), high virus excretion level (108 to 
1010  copies of RNA per gram of feces) and extended ex-
cretion after clinical recovery18,19. The virus is replicated in 
the enterocyte cytoplasm, where the positive polarity RNA 
acts as mRNA. Studies showed the virus elimination can 
continue for over 2 weeks after the symptomatic phase of 
the disease, as well as  cases of  asymptomatic infection 20 
with an implication on outbreaks caused by food transmis-
sion diseases21. There is little evidence that NoVs can cause 
a chronic infection in a normal host; however, a study per-
formed in immunocompromised children and adolescents 
by Levett et al.22 reported NoV GII shedding over at least 
8 months.
TRANSMISSION
NoVs are the main cause of acute nonbacterial human 
gastroenteritis, being transmitted from food or from per-
son to person via a fecal-oral route, affecting adults and 
children all over the world23. Indirect evidence in epide-
miological studies suggests the virus transmission can be 
airborne, such as in explosive vomiting occurred during 
the disease24. Transmission can also occur via water reser-
voir when groundwater is contaminated25. They are highly 
contagious, possibly occurring in either sporadic cases 
or in great acute diarrhea outbreaks in wards, hospitals, 
schools, universities, camping places, cruises, hotels, and 
restaurants26. Food quality control is often based on bacte-
rial contamination; thus, virus contamination may not be 
reported often27. Virus transmission in hospital wards is 
difficult to identify26. Filtering animals living in contami-
nated waters and which are eaten raw, such as oysters, are 
major transmission routes28.
Clinical features are characterized by nausea, abdomi-
nal pain, vomiting, mild, self-limited, and non-bloody 
diarrhea. However, some patients can have severe forms, 
with symptoms linked to nausea and vomiting, followed 
by copious diarrhea, which can result in dehydration and 
occasionally death. Incubation period is 24 to 48  hours, 
with the symptoms lasting 12 to 60 hours29. Low fever and 
abdominal pain can also be associated with a virus infec-
tion, with the term “stomach flu” being used to describe 
the disease, although no biological association with in-
fluenza virus can be found. Approximately 10% of people 
with NoV require a medical visit, including hospitalization 
and dehydration treatment. Deaths caused by NoV are 
more frequently reported in elderly people. Around 30% 
of infections from NoV are asymptomatic; however, these 
individuals can transmit the virus, although in lower levels 
than symptomatic individuals30.
IMMUNITY
Because of a lack of animal model and resources to grow 
this virus in cell cultures, in vitro neutralization tests are 
not feasible, and data of immunity development after 
NoV infection is obtained from human studies with vol-
unteers31. Studies indicate approximately 50% of people 
exposed to the virus acquired short-term homologous im-
munity, which is correlated with the serum antibody lev-
el32. However, people with preexisting high antibody levels 
to NoV may become ill if exposed to the virus26,32. A candi-
date vaccine has been developed, although it is not known 
whether the vaccine induces homotypic or heterotypic im-
mune protection31,33. As no suitable prevention and con-
trol method is available, the development of a vaccine to 
NoV could be the best solution for this infectious disease34. 
Studies suggest there is a short-term immunity after infec-
tion, and some individuals are susceptible to symptomatic 
infection, whereas others never develop symptoms, even 
after a direct contact32.
PREVENTION AND TREATMENT
Stopping transmission is the first strategy for prevention, 
especially in hospitals and day-care centers. A number of 
precautions, such as hand washing with water and soap 
before and after contacting the patient or objects used by 
him/her, must be taken when caring for a patient diag-
nosed with an acute gastroenteritis. It is also required to 
clean all surfaces with 2% hypochlorite35, as NoV persist 
in dry inanimate surfaces over eight hours to seven days36. 
To avoid secondary transmissions, prevention of food 
contaminations during the preparation by a continuous 
hand washing is required. Those who handle food must 
wear plastic gloves when preparing raw food37. Affected 
workers must not prepare food for a minimum period of 
three days after the disease to avoid gastroenteritis out-
breaks38.
As there is no strengthened antivirus agent to treat nor-
ovirus diseases, the focus consists of prevention and treat-
ment of the secondary dehydration. Fluid therapy is usu-
ally maintained orally with isotonic fluids. Hospitalization 
in cases of a severe dehydration may be required, although 
this is rare. Symptoms such as headache, myalgia, and nau-
sea can be treated with analgesic and antipyretic drugs39. 
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In 2006, Rossignol40 analyzed a new drug, the nitazoxanide, 
indicated to treat diarrhea caused by virus gastroenteritis. 
In this study, the drug efficacy in several patients with 
symptoms and positive diagnosis for rotavirus, enteric ad-
enovirus, norovirus, and astrovirus was observed. Howev-
er, higher drug effectiveness was found against rotavirus, 
compared with other viral pathogens.
LABORATORY DIAGNOSIS
The classic diagnosis method is electron microscopy (EM), 
detecting virus particles with 27 to 30 nm in diameter, the 
so-called SRSV. This method is used in public health labo-
ratories in many countries; however, it requires a highly 
qualified microscopist and very expensive equipment, 
making epidemiological or clinical studies impracticable41.
The immunoenzymatic method (ELISA) to detect the 
virus antigen uses norovirus capsid proteins expressed on 
baculovirus as a reactant in immunoenzymatic tests29. This 
method has been recently made commercially available to 
diagnose NoV directly from feces (Dako Cytomation, Ely, 
UK 2001; Denka Seiken, Tokyo, Japan, 2002; R-Biopharm 
AG, Germany 2004). These kits have low diagnostic sen-
sitivity, as reported by Bull et al.42. However, the develop-
ment of new kit generations, such as RIDASCREEN 3rd 
Generation kit (R-Biopharm AG, Darmstadt, Germany), 
which is more sensitive and specific, entailed benefits for 
NoV quick diagnosis, mainly targeting outbreaks43.
The RT-PCR molecular technique, developed to iden-
tify NoV, is sensitive and specific, enabling epidemiologi-
cal studies to identify gastroenteritis outbreaks44. Interna-
tional collaborative studies45 demonstrated that, among 
several primer pools developed for regions ORFs 1, 2, and 
3, those showing the best results were primers in POL re-
gion of ORF 1 (preserved region). Phylogenetic analysis of 
145 nucleotides in the POL gene region was used as a pat-
tern to identify genotypes. NoV sequencing has assisted 
in epidemiological investigations relating clinical cases to 
determine a common source and to differentiate outbreaks 
that could be wrongly related45.
REAL-TIME TaqMan46,47 RT-PCR and SYBR Green48 
techniques quantify specific DNA or RNA sequences 
in clinical samples and the gene expression from emit-
ted fluorescence detection since the first amplification 
cycle. These methods have advantages over regular PCR, 
such as higher specificity, sensitivity, and reproducibil-
ity, in addition to allowing real-time monitoring; quicker 
cycling; lower RNA amount in RT-PCR reactions; and 
elimination of post-PCR product handling, thus reduc-
ing contamination45.
EPIDEMIOLOGY
NoVs are considered the most common viral etiologic 
agents in outbreaks of virus gastroenteritis transmitted by 
water and food49. The epidemiology of diarrheal diseases 
transmitted by water and food is quickly changed from the 
human behavior changes concerning global economy, 
the industry, and microbiological adaptations. The high-
est disease incidence is among children under five years 
of age50. However, the highest economic impact is among 
elderly residing in nursing homes51. Although diarrhea 
outbreaks can occur all over the year, some seasonality 
patterns have been observed. These patterns are differ-
ent in Northern and Southern hemispheres. In Northern 
hemisphere, gastroenteritis caused by NoV is more com-
monly seen in winter and early spring22. In the Southern 
hemisphere, outbreaks are more frequent over the spring 
and summer52.
From 1999 to 2002, 170 NoV outbreaks occurred in 
Spain. By employing EM, RT-PCR and sequencing tech-
niques, the genogroup GII was observed as predominat-
ing53. In England, Lopman et al.51, by analyzing samples 
from outbreaks occurred between 1995 and 2002, ob-
served NoV had a peak infection over the summer, in 
contrast with the reports from that time, describing higher 
occurrence in the winter.
Chapin et al.54 found NoV transmission from food 
contamination crosses borders; the virus from the United 
States reached Guatemala and Mexico, and the samples 
were analyzed by RT-PCR and sequencing, with NoV 
genogroup GI being identified in 65% of positive cases.
In the state of São Paulo, during the summer of 1995, a 
gastroenteritis outbreak occurred, affecting around 3,500 
people (CVE data). EM analysis of fecal samples from this 
outbreak detected virus particles with SRSV morphology 
identified as Norwalk-like by immunoelectron micros-
copy (IEM)55. These samples were further analyzed by 
RT-PCR and sequencing and characterized as calicivirus 
SMA (Snow Mountain Agent) type, currently termed GII 
genogroup NoV56.
From 2005 to 2008, a surveillance NoV study was con-
ducted in the state of Rio de Janeiro. A total 1,087 fecal 
samples were analyzed and about 35% were positive for 
NoV, with a 96% prevalence of GII genogroup and 80% 
GII.4; the requirement of implanting NoV diagnosis in the 
surveillance laboratories was described57.
In the state of São Paulo, also in 2005, several gastroen-
teritis outbreaks occurred in children and adolescents, and 
the sample analysis demonstrated the circulation of differ-
ent viruses around the same region. NoVs were detected in 
21.4% of samples, followed by rotavirus, with 14.5%, astro-
virus with 13.2%, and adenovirus with 2.1%58.
CONCLUSION
The Nucleus of Enteric Diseases of Instituto Adolfo Lutz 
(IAL) is a macroregional reference for rotavirus and noro-
virus vigilance in the Acute Diarrheal Disease Monitoring 
Program (PMDDA), aiming at the early detection of di-
arrhea outbreaks all over the country. In 2008, systematic 
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implementation for NoV detection was initiated to detect 
NoV in IAL59. In 2009, with the enhancement of conduct-
ing, 15 identified NoV outbreaks were detected in Catan-
duva, Mongaguá, Piracicaba, Pitangueiras, Praia Grande, 
Ribeirão Preto, Sabino, São Paulo, Taubaté, Votuporanga60. 
In January 2010, Guarujá, in Baixada Santista, faced a 
severe diarrhea outbreak with NoV (28%) and rotavirus 
(20%) (data from IAL). The easiness with which norovi-
ruses are transmitted and the low infecting dose required 
to set an infection results in extensive outbreaks. The accu-
rate diagnosis of virus gastroenteritis is essential to reduce 
the impact of the disease on the society.
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